Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5451]
News [12661]
Articles [175]
Editorials [5]
Conferences [249]
elearning [17]
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer
Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer ( Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA )
22 Sep 2020
ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer
Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan
ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer ( Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004 ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
22 Sep 2020
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC...
Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection ( Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers
Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers ( Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany )
22 Sep 2020
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
22 Sep 2020
Amivantamab lazertinib and other novel combinations in EGFR positive advanced...
Dr Alex Spira and Dr Joshua Sabari
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC ( Dr Alex Spira and Dr Joshua Sabari )
21 Sep 2020
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer
Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer ( Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK )
21 Sep 2020
LungART: Radiotherapy after surgery for patients with non small cell lung cancer
Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France
LungART: Radiotherapy after surgery for patients with non small cell lung cancer ( Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France )
21 Sep 2020
Personalised molecularly matched therapies for carcinomas of unknown primary
Dr Jacob Adashek - University of South Florida, Tampa, USA
Personalised molecularly matched therapies for carcinomas of unknown primary ( Dr Jacob Adashek - University of South Florida, Tampa, USA )
21 Sep 2020
Comparing real world evidence to phase III data on apalutamide for nmCRPC
Prof Heather Payne and Prof Stéphane Oudard
Comparing real world evidence to phase III data on apalutamide for nmCRPC ( Prof Heather Payne and Prof Stéphane Oudard )
19 Sep 2020
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC
Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC ( Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France )
19 Sep 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation